How does chemo during pregnancy affect child development?
Chemotherapy performed on women during pregnancy could adversely affect long-term...Read more on AuntMinnie.comRelated Reading: MRI brain scans show benefits of prenatal folic acid Fetal MRI can spot early brain abnormality MRI shows maternal depression meds affect babies' brains MRI links blood flow to brain development in preterm babies MRI scans during 1st trimester of pregnancy are safe (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - May 21, 2019 Category: Radiology Source Type: news

UNDER THE MICROSCOPE: Loose Women TV presenter Andrea McLean, 49, answers our health quiz
The TV presenter is currently training for a 10K run, hits the gym three times per-week and is lactose-intolerant. She also suffered with postnatal depression. (Source: the Mail online | Health)
Source: the Mail online | Health - May 20, 2019 Category: Consumer Health News Source Type: news

Book Review: Birth of a New Brain: Healing from Postpartum Bipolar Disorder
“I was caught in a whirl of racing, obsessive thoughts, which is how many people describe their bouts of mania. Instead of noticing my baby girl’s sweet scent or feeling her rose-petal soft skin, all I could think was, I must write this idea down, and this, and this…,” writes Dyane Harwood. In her new book, Birth of a New Brain: Healing from Postpartum Bipolar Disorder, Harwood offers an unfiltered, unedited and heart-wrenching journey through postpartum bipolar disorder and reminds us all that, even in the seemingly worst circumstances, hope can remain. Harwood’s story begins in the delivery...
Source: Psych Central - May 20, 2019 Category: Psychiatry Authors: Claire Nana Tags: Bipolar Book Reviews Disorders Family General Medications Memory and Perception Motivation and Inspiration Personal Stories Postpartum Depression Psychological Assessment Psychology Stigma Stress Suicide Treatment Women's I Source Type: news

Erratum to: Oxytocin and maltreatment potential : Influence of maternal depression, borderline personality disorder and experience of early childhood maltreatment - Kluczniok D, Dittrich K, Hindi Attar C, B ödeker K, Roth M, Jaite C, Winter S, Herpertz SC, Roepke S, Heim C, Bermpohl F.
[Abstract unavailable] Language: de... (Source: SafetyLit)
Source: SafetyLit - May 18, 2019 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news

Why Munchausen Syndrome by Proxy Is Having a Moment on TV
Munchausen syndrome by proxy is having an unexpected moment—at least on television. The medical disorder, which manifests when a person “acts as if an individual he or she is caring for has a physical or mental illness when the person is not really sick,” according to the Cleveland Clinic, has appeared in a number of shows and movies in recent years. It has anchored the twists of HBO’s thriller series Sharp Objects and Paul Thomas Anderson’s 2017 film Phantom Thread. European shows, including The Bridge and the BBC Three’s Clique, have also included Munchausen in their plots. The rise in...
Source: TIME: Health - May 16, 2019 Category: Consumer Health News Authors: Mahita Gajanan Tags: Uncategorized Television Source Type: news

Assess benzodiazepines ’ risk-benefit before use in early pregnancy
Study shows strong association of spontaneous abortion with taking benzodiazepines in early pregnancy Related items fromOnMedica MHRA tightens licence restrictions on valproate for women Tool helps GPs predict risk of epilepsy seizures in pregnancy Postnatal depression missed far more often in dads than mums Include pregnant women in studies, urge researchers Most CCGs missing smoking target for pregnant women (Source: OnMedica Latest News)
Source: OnMedica Latest News - May 16, 2019 Category: UK Health Source Type: news

Postpartum depression: For impoverished mothers of color, it takes a community
(University at Buffalo) Treating postpartum depression (PPD) in low-income mothers of color requires an understanding of each person's lived experience, and practitioners should consider interventions that develop broadly from a community level in order to improve outcomes for their clients, according to a University at Buffalo social work researcher. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - May 14, 2019 Category: International Medicine & Public Health Source Type: news

Postnatal depression missed far more often in dads than mums
Far more must be done to improve understanding of paternal PND so it ’s not brushed off as simply stress Related items fromOnMedica Armed forces wives at greater risk of perinatal depression Well over half of people have never had an STI test Most CCGs missing smoking target for pregnant women Maternity care better in some respects – but still many problems Assess pregnant and new mums ’ mental health (Source: OnMedica Latest News)
Source: OnMedica Latest News - May 14, 2019 Category: UK Health Source Type: news

The impact of objective and subjective sleep parameters on depressive symptoms during pregnancy in women with a mental disorder: an explorative study - Bais B, Lindeboom R, van Ravesteyn L, Tulen J, Hoogendijk W, Lambregtse-van den Berg M, Kamperman A.
This study evaluated both objective and subjective sleep quality and the effects on the subsequent course of antepartum depressive ... (Source: SafetyLit)
Source: SafetyLit - May 13, 2019 Category: International Medicine & Public Health Tags: Suicide and Self-Harm Source Type: news

Study shows people fail to recognise male postnatal depression
(Anglia Ruskin University) A new study shows that people are almost twice as likely to correctly identify signs of postnatal depression in women than in men. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - May 13, 2019 Category: International Medicine & Public Health Source Type: news

Consequences of maternal postpartum depression: a systematic review of maternal and infant outcomes - Slomian J, Honvo G, Emonts P, Reginster JY, Bruyere O.
INTRODUCTION: The postpartum period represents the time of risk for the emergence of maternal postpartum depression. There are no systematic reviews of the overall maternal outcomes of maternal postpartum depression. The aim of this study was to evaluate b... (Source: SafetyLit)
Source: SafetyLit - May 3, 2019 Category: International Medicine & Public Health Tags: Age: Infants and Children Source Type: news

Postpartum depression is one of the most common complications of childbirth. Researchers are homing in on risk factors.
Findings from a study show that it can vary in severity, which can affect the type of treatment a woman might need to recover. (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - April 20, 2019 Category: Consumer Health News Authors: Juli Fraga Source Type: news

'Netball made me the person I was before depression'
Shaharun Nessa took up netball after suffering postnatal depression and now runs a group for women. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - April 16, 2019 Category: Consumer Health News Source Type: news

Newly Approved Drug a'Revolution' for Postpartum Depression Newly Approved Drug a'Revolution' for Postpartum Depression
The marked improvement in postpartum depression within 60 hours of intravenous brexanolone infusion is sustained over 30 days, with half of patients still responding, a pooled analysis of three RCTs shows.Medscape Medical News (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - April 9, 2019 Category: Primary Care Tags: Psychiatry News Source Type: news

Prevalence and related factors of postpartum depression among reproductive aged women in Ahvaz, Iran - Afshari P, Tadayon M, Abedi P, Yazdizadeh S.
This study started in February a... (Source: SafetyLit)
Source: SafetyLit - April 3, 2019 Category: International Medicine & Public Health Tags: Age: Young Adults Source Type: news

Mother-of-four, 31, shares a moving post about what postnatal depression really looks like
Mother-of-four, Mel Watts, shared the photo of herself and her youngest daughter Indie in a shower to highlight the reality of the post-natal depression she was suffering at the time. (Source: the Mail online | Health)
Source: the Mail online | Health - April 2, 2019 Category: Consumer Health News Source Type: news

The dynamic course of peripartum depression across pregnancy and childbirth - Dekel S, Ein-Dor T, Ruohom äki A, Lampi J, Voutilainen S, Tuomainen TP, Heinonen S, Kumpulainen K, Pekkanen J, Keski-Nisula L, Pasanen M, Lehto SM.
OBJECTIVE: Peripartum depression (PPD) pertaining to depression in pregnancy and postpartum is one of the most common complications around childbirth with enduring adverse effects on mother and child health. Although psychiatric symptoms may improve or wor... (Source: SafetyLit)
Source: SafetyLit - March 30, 2019 Category: International Medicine & Public Health Tags: Age: Infants and Children Source Type: news

Maternal unwanted and intrusive thoughts of infant-related harm, obsessive-compulsive disorder and depression in the perinatal period: study protocol - Collardeau F, Corbyn B, Abramowitz J, Janssen PA, Woody S, Fairbrother N.
BACKGROUND: Unwanted, intrusive thoughts of harm-related to the infant are reported by the vast majority of new mothers, with half of all new mothers reporting unwanted, intrusive thoughts of harming their infant on purpose. Thoughts of intentional harm, i... (Source: SafetyLit)
Source: SafetyLit - March 26, 2019 Category: International Medicine & Public Health Tags: Age: Infants and Children Source Type: news

Mothers of fussy babies at higher risk of depressive symptoms
(Michigan Medicine - University of Michigan) As FDA approval of the first postpartum depression drug hits the news, study looks at how infant fussiness and a baby's level of prematurity may influence the severity of maternal depressive symptoms. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - March 25, 2019 Category: International Medicine & Public Health Source Type: news

The burden and risk factors for postnatal depression and depressive symptomatology among women in Kampala - Nampijja M, Natamba B, Mpango R, Kinyanda E.
Major depressive disorder (MDD) is a major global health challenge and postnatal women may be at an increased risk for this disorder. Very few studies have tested this hypothesis in sub-Saharan Africa (SSA), so it is uncertain whether risk factors implicat... (Source: SafetyLit)
Source: SafetyLit - March 24, 2019 Category: International Medicine & Public Health Tags: Suicide and Self-Harm Source Type: news

How the first postpartum depression drug works
This week the Food and Drug Administration approved the first treatment specifically targeting postpartum depression, a condition that can impact women following childbirth, sometimes even starting during pregnancy. Symptoms can include sadness, loss of energy and feelings of guilt and worthlessness. Dr. David Agus joins "CBS This Morning: Saturday" to discuss how the new drug works and how a new personalized video game can help stroke victims. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - March 23, 2019 Category: Consumer Health News Source Type: news

D.C. Week: Postpartum Depression Gets Its Own Drug
(MedPage Today) -- Also, a novel Alzheimer's therapy deemed unready for prime time (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - March 22, 2019 Category: Psychiatry Source Type: news

FDA: First Treatment Approved Specifically for Postpartum Depression
Zulresso administered by IV infusion over 60 - hour period; patients must be monitored during infusion (Source: The Doctors Lounge - Psychiatry)
Source: The Doctors Lounge - Psychiatry - March 20, 2019 Category: Psychiatry Tags: Family Medicine, Gynecology, Pharmacy, Psychiatry, Institutional, Source Type: news

Drug to treat postpartum depression approved in U.S.
First postpartum depression therapy, an IV drug, approved by U.S. Food and Drug Administration. (Source: CBC | Health)
Source: CBC | Health - March 20, 2019 Category: Consumer Health News Tags: News/Health Source Type: news

Blog Post » A Bench-to-Bedside Story: The Development of a Treatment for Postpartum Depression
In this message, Dr. Gordon discusses the role of NIMH and others in the bench-to-bedside story of bexanolone, which has just been approved by the FDA as the first treatment specifically for postpartum depression. (Source: National Institute of Mental Health)
Source: National Institute of Mental Health - March 20, 2019 Category: Psychiatry Authors: Joshua Gordon Source Type: news

Science News » Bench-to-Bedside: NIMH Research Leading to Brexanolone, First-Ever Drug Specifically for Postpartum Depression
FDA approval of the postpartum depression treatment brexanolone represents the final phase of a bench-to-bedside journey for this drug — a journey that began in the NIMH Intramural Research Program. NIMH experts are available to provide information on postpartum depression and the importance of, and the science underlying, this new drug. (Source: National Institute of Mental Health)
Source: National Institute of Mental Health - March 20, 2019 Category: Psychiatry Authors: Claire Cole Source Type: news

FDA approves new treatment for postpartum depression
The FDA has approved biopharma Sage Therapeutics' first product, a drug that the company says will be the first product specifically designed to treat postpartum depression. Zulresso is Sage's (Nasdaq: SAGE) first product to reach the market and one of two treatments the company has developed to treat postpartum depression. Its second potential therapy, an oral medication known as SAGE 217, succeeded in a late-stage trial as a postpartum treatment and is also being ev aluated as a potential major… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - March 20, 2019 Category: American Health Authors: Allison DeAngelis Source Type: news

First Drug for Postpartum Depression Gets FDA Nod
(MedPage Today) -- " Important new treatment option " for women suffering from post-partum depression, agency says (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - March 20, 2019 Category: Psychiatry Source Type: news

Bench-to-bedside: NIMH research leads to brexanolone, first-ever drug specifically for postpartum depression
Approximately 1 in 9 women in the United States experiences symptoms. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - March 20, 2019 Category: American Health Source Type: news

FDA Approves First Drug for Postpartum Depression
The drug, Zulesso (brexanolone), is delivered via intravenous infusion. (Source: WebMD Health)
Source: WebMD Health - March 20, 2019 Category: Consumer Health News Source Type: news

FDA Approves Cambridge Company ’s Groundbreaking Drug For Postpartum Depression
(CNN) — For the first time in history, the US Food and Drug Administration has approved a drug specifically indicated for the treatment of postpartum depression, which experts say offers new hope to women and physicians. On Tuesday, the FDA announced the approval of an intravenous infusion of the drug brexanolone, which will be sold as Zulresso. It has been shown in clinical trials to work within hours to treat the symptoms of postpartum depression, a serious mental illness that impacts 1 in 9 new mothers after childbirth. The first drug to treat postpartum depression was approved by the FDA Tuesday. In the U.S., ...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - March 20, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Health CNN FDA Postpartum Depression Source Type: news

FDA approves first drug to treat postpartum depression
U.S. regulators have approved the first medication specifically for women with postpartum depression, which the drug maker calls a breakthrough treatment. (Source: Health News - UPI.com)
Source: Health News - UPI.com - March 20, 2019 Category: Consumer Health News Source Type: news

Woman "noticed a huge difference" after postpartum depression treatment
The FDA just approved the first drug to treat postpartum depression. The condition affects more than 400,000 women every year, an estimated 20 percent of new moms in the U.S. Dr. Tara Narula spoke to one of the handful of women who have tried the drug and shows us its dramatic results. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - March 20, 2019 Category: Consumer Health News Source Type: news

Sage Therapeutics wins first FDA postpartum approval
The U.S. FDA has approved Sage Therapeutics'Zulresso, the first drug approved by the agency specifically to treat postpartum depression. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - March 20, 2019 Category: Pharmaceuticals Source Type: news

Sage wins historic FDA nod for postpartum depression therapy
Sage Therapeutics (NSDQ:SAGE) this week won FDA approval for the first medicine indicated to treat postpartum depression. The Cambridge, Mass.-based company’s injection therapy, Zulresso, is slated to be available in late June. Postpartum depression is the most common medical complication of childbirth, according to Sage, and affects roughly one in nine women who have given birth in the U.S. Get the full story at our sister site, Drug Delivery Business News. The post Sage wins historic FDA nod for postpartum depression therapy appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - March 20, 2019 Category: Medical Devices Authors: Sarah Faulkner Tags: Business/Financial News Drug-Device Combinations Featured Food & Drug Administration (FDA) Neurological Pharmaceuticals Wall Street Beat sagetherapeutics Source Type: news

FDA: First Treatment Approved Specifically for Postpartum Depression
WEDNESDAY, March 20, 2019 -- Zulresso (brexanolone) injection has been approved for intravenous (IV) use in the treatment of postpartum depression (PPD) in adult women, marking the first drug approved specifically for PPD, the U.S. Food and Drug... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 20, 2019 Category: Pharmaceuticals Source Type: news

FDA Approves First Drug for Postpartum Depression, Brexanolone (Zulesso)
WEDNESDAY, March 20, 2019 -- Postpartum depression is a common and often devastating condition for new mothers, but the U.S. Food and Drug Administration on Tuesday approved the first drug to help combat it. The drug, Zulesso (brexanolone), is... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 20, 2019 Category: General Medicine Source Type: news

FDA Approves First Drug for Postpartum Depression, Zulresso (brexanolone)
WEDNESDAY, March 20, 2019 -- Postpartum depression is a common and often devastating condition for new mothers, but the U.S. Food and Drug Administration on Tuesday approved the first drug to help combat it. The drug, Zulresso (brexanolone), is... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 20, 2019 Category: General Medicine Source Type: news

The F.D.A. Just Approved the First Drug for Postpartum Depression
The Food and Drug Administration approved the first drug specifically for the treatment of postpartum depression Tuesday. The drug, which is administered via an intravenous drip, reportedly works within 48 hours, providing near immediate relief to women experiencing symptoms, according to the New York Times. Postpartum depression has historically been treated with counseling or general antidepressants, which can take weeks to kick in or may not work at all. The newly-approved drug, brexanolone, will be marketed as Zulresso. The treatment will be offered only as an in-patient option at certified medical centers because it c...
Source: TIME: Health - March 20, 2019 Category: Consumer Health News Authors: Amy Gunia Tags: Uncategorized Health Care onetime overnight Source Type: news

The FDA Just Approved the First Drug for Postpartum Depression
The Food and Drug Administration approved the first drug specifically for the treatment of postpartum depression Tuesday. The drug, which is administered via an intravenous drip, reportedly works within 48 hours, providing near immediate relief to women experiencing symptoms, according to the New York Times. Postpartum depression has historically been treated with counseling or general antidepressants, which can take weeks to kick in or may not work at all. The newly-approved drug, brexanolone, will be marketed as Zulresso. The treatment will be offered only as an in-patient option at certified medical centers because it c...
Source: TIME: Health - March 20, 2019 Category: Consumer Health News Authors: Amy Gunia Tags: Uncategorized Health Care onetime overnight Source Type: news

FDA approves a new postpartum depression treatment
The drug rebalances hormones that spike during pregnancy and plummet after birth (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - March 20, 2019 Category: Consumer Health News Source Type: news

F.D.A. Approves First Drug for Postpartum Depression
The medication works quickly, within 48 hours. But it ’ s an expensive infusion and requires a stay in a medical center. (Source: NYT Health)
Source: NYT Health - March 20, 2019 Category: Consumer Health News Authors: PAM BELLUCK Tags: your-feed-science Depression (Mental) Drugs (Pharmaceuticals) Antidepressants Pregnancy and Childbirth Food and Drug Administration Source Type: news

FDA approves new treatment for postpartum depression
The FDA has approved the first drug specifically designed to treat postpartum depression. In the U.S., about one in nine mothers experience depression after having a baby. As Dr. Tara Narula reports, the new drug is providing hope. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - March 20, 2019 Category: Consumer Health News Source Type: news

First drug specifically for postpartum depression is approved
The Food and Drug Administration approved the first drug developed specifically for postpartum depression, a debilitating condition that affects hundreds of thousands of women a year in the United States. (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - March 20, 2019 Category: Consumer Health News Authors: Laurie McGinley Source Type: news

FDA Approves Brexanolone (Zulresso), First Drug for Postpartum Depression FDA Approves Brexanolone (Zulresso), First Drug for Postpartum Depression
The drug can be given only in a certified facility, and women will have to stay for the entire 2.5 days it takes for the infusion.FDA Approvals (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - March 20, 2019 Category: Psychiatry Tags: Ob/Gyn & Women ' s Health News Alert Source Type: news

FDA approves the first drug designed to treat postpartum depression
The Food and Drug Administration on Tuesdayapproved the first drug specifically forpostpartum depression, a debilitating condition that affects about 400,000 women a year in the United States.The disorder, which begins during pregnancy or within a month of childbirth, is far more severe than... (Source: Los Angeles Times - Science)
Source: Los Angeles Times - Science - March 20, 2019 Category: Science Authors: Laurie McGinley, Lenny Bernstein Source Type: news

FDA approves first postpartum depression drug
(Source: CNN.com - Health)
Source: CNN.com - Health - March 20, 2019 Category: Consumer Health News Source Type: news

Sage gets U.S. approval for first postpartum depression therapy
The U.S. Food and Drug Administration on Tuesday approved Sage Therapeutics Inc's drug for postpartum depression, marking the first approval of a treatment specifically developed for the condition that affects a new mother's ability to care for herself or her baby. (Source: Reuters: Health)
Source: Reuters: Health - March 20, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

FDA Approves Zulresso (brexanolone) for the Treatment of Postpartum Depression
March 19, 2019 -- The U.S. Food and Drug Administration today approved Zulresso (brexanolone) injection for intravenous (IV) use for the treatment of postpartum depression (PPD) in adult women. This is the first drug approved by the FDA... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 19, 2019 Category: Drugs & Pharmacology Source Type: news

FDA approves Sage's first-ever treatment for postpartum depression
The FDA has approved Cambridge biopharma Sage Therapeutics' first product, a drug that the company says will be the first product specifically designed to treat postpartum depression. Zulresso is Sage's (Nasdaq: SAGE) first product to reach the market and one of two treatments the company has developed to treat postpartum depression. Its second potential therapy, an oral medication known as SAGE 217, succeeded in a late-stage trial as a postpartum treatment and is also being ev aluated as a potential… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - March 19, 2019 Category: American Health Authors: Allison DeAngelis Source Type: news